April 2026 Research Update

What treatment research looked like this month

This month added early, small-scale signals that very targeted immune treatments might control AL amyloidosis even after multiple prior treatments, while also showing why safety follow-up matters. One small CAR-T study reported very fast and deep blood responses with kidney improvement, and a separate lab study tested a drug combination that could potentially help when proteasome inhibitor drugs stop working. Together, these studies broaden the list of approaches being explored, but they are not yet at the stage of proving what will work for most people.

In six people with relapsed or refractory AL amyloidosis, a single infusion of BCMA-CD19 dual-targeted CAR-T cells led to hematologic complete response and renal response in all participants, with a median of 9 days to blood response and 75 days to kidney response. Side effects were mostly mild cytokine release syndrome in 2 people, with pneumonia in 2 people, and there were no reported neurotoxicity cases; one person later developed acute promyelocytic leukemia 15 months after CAR-T. The study also reported cell-level testing consistent with clearance of abnormal plasma cells and recovery of the immune system after treatment. [1]

In laboratory and zebrafish model work that included AL amyloidosis cells, bedaquiline (a drug used for some infections) or bedaquiline-fumarate combined with carfilzomib (a proteasome inhibitor used in related plasma cell diseases) increased cancer cell killing compared with either drug alone. The authors reported low toxicity toward normal cells in these experiments and proposed a mitochondrial target that may help explain the effect. This is an early research step, because the results come from models rather than people with AL amyloidosis. [2]

A separate computer-based study designed a small peptide intended to interfere with a patient-derived AL light chain dimer, and the optimized peptide bound the light chain with an affinity similar to the natural dimer interface. If this kind of approach holds up in future lab and animal testing, it could become a way to target the light chains themselves, rather than only the cells that make them. For now, it mainly shows a possible direction for drug development rather than a near-term option. [3]

One detailed patient report also described prominent autonomic nerve problems (such as fainting and digestive symptoms) improving gradually over 6 months after a daratumumab-based regimen, alongside complete hematologic remission. Because it is a single patient, it cannot show how often this kind of nerve recovery happens, but it adds to the picture that symptom changes can lag behind blood response and may improve over time in some people. [4]

What this may mean for patients and caregivers

These studies mainly matter as early signals about what could be possible in the future, especially for people whose AL amyloidosis has come back or not responded well. The CAR-T report suggests that deep blood responses and kidney responses can happen quickly in a very small group, but it also shows why longer follow-up is important to understand durability and uncommon risks. The lab and computer studies expand the pipeline of ideas, but they do not yet tell us what will help patients in day-to-day care because they have not been proven in people.

What became clearer about testing

This month strengthened a practical message: diagnosing AL amyloidosis depends on both detecting the abnormal light-chain protein and correctly typing the amyloid in tissue. Studies looking at blood and urine tests showed that combining methods catches more cases than relying on a single test, and a guideline reinforced that tissue confirmation and careful subtyping are central. Other work explored faster or newer tools (like bone marrow smear review and mass spectrometry-based protein detection) that could complement current testing in some settings.

A large meta-analysis reported that using serum immunofixation, urine immunofixation, and the serum free light chain ratio together had very high sensitivity (0.99) for detecting the underlying plasma cell disorder in AL amyloidosis. In plain terms, this supports the idea that a combination of blood and urine testing is better at picking up low-level disease signals than any single test alone. This kind of evidence helps explain why multiple tests are often paired when AL amyloidosis is being considered. [5]

A separate real-world testing study found that urine immunofixation sometimes detected a monoclonal protein even when the paired serum immunofixation test was negative, in about 5% of cases. Kidney function and serum free light chain results did not explain who had this mismatch, meaning the discordant result was not easy to predict in advance. For patients, this highlights how urine testing can occasionally pick up a clue that blood testing misses. [6]

On the tissue side, a Belgian consensus document emphasized that amyloidosis diagnosis and typing still relies on biopsy tissue that is Congo red-positive, followed by subtyping tests, with mass spectrometry used when results are unclear. The guidance also encouraged centralizing complex amyloid typing in experienced centers, reflecting how much accuracy can depend on specialized methods. For patients, this underlines why getting the amyloid type right is a key step before anyone can interpret what the diagnosis means. [7]

Two studies evaluated additional tools that could support diagnostic workups. In 252 people with systemic AL amyloidosis, bone marrow smear review closely matched bone marrow biopsy for detecting amyloid deposits, with 98% concordance, suggesting smear review could serve as a rapid screening add-on when paired with biopsy. In another diagnostic evaluation across plasma cell disorders that included AL amyloidosis, serum-based MALDI-TOF mass spectrometry detected M-protein frequently and sometimes captured additional features like light-chain glycosylation, with preliminary treatment-response observations in a small subset. [8] [9]

For cardiac AL suspicion in a high-risk hospital setting, one prospective study in heart failure patients with a monoclonal gammopathy reported that thicker left ventricular posterior wall thickness on echocardiography predicted cardiac AL better than the blood light-chain difference measure they tested. Combining the wall thickness measure with the blood marker did not outperform the wall thickness measure alone in this dataset. This adds to the picture that routine heart imaging findings can carry meaningful diagnostic clues in the right clinical context. [10]

What this may mean for patients and caregivers

This month mainly adds clarity about how AL is found and confirmed, rather than pointing to a new single best test. The strongest takeaway is that combining blood and urine protein tests can improve the chance of detecting the underlying light-chain problem, and that biopsy-based typing remains the anchor for knowing what kind of amyloid is present. Some newer or faster approaches (bone marrow smear review and mass spectrometry-based protein detection) may matter more in the future as they are validated and adopted, but the studies here do not establish one standard pathway for everyone.

What the month showed about outcomes

This month added a more detailed, organ-by-organ picture of what improvement can look like in AL amyloidosis, and what risks still need attention. Several studies reinforced that deeper control of the light-chain source connects to better outcomes, but organ recovery may be incomplete and can take time. Other work highlighted complications patients may face, including blood clots and procedure-related risk, and showed that not every proposed heart imaging marker performs well in advanced disease.

In a large single-center cohort of cardiac AL amyloidosis, only 63 of 1,342 evaluable people achieved a cardiac biomarker complete response, and it typically happened months after blood response, with a median time of about 21 months. Heart ultrasound measures improved by the time people reached this biomarker milestone, but some structural abnormalities remained. Survival in this group was reported as comparable to a matched general U.S. population, even though some later had cardiac progression or needed additional clone-directed therapy. [11]

In people with symptomatic gastrointestinal involvement from systemic AL amyloidosis, prognosis differed depending on where amyloid was seen in GI tissue and on broader disease factors like cardiac stage and hematologic response. Mucosal involvement was common and linked to bleeding and worse survival, and combined involvement of mucosa, submucosa, and vessels had the shortest reported median survival. The study also emphasized that autonomic nerve dysfunction can drive digestive symptoms even when GI biopsies do not show amyloid, and that cachexia and persistent diarrhea were major drivers of illness and nutritional support needs. [12]

For clotting risk, a prospective cohort study reported that thrombosis occurred in 32.8% of patients, and that specialized blood clotting tests were linked to both having a clot and to clot recurrence, while standard clotting times were not predictive. The study also reported that markers of inflammation and fibrin turnover tracked with one of these hypercoagulability test results. For patients, this helps explain why clot risk in AL may not be well captured by routine clotting labs alone in some settings. [13]

In advanced cardiac AL (stage IIIb) in the daratumumab era, one study found that a proposed global longitudinal strain cutoff did not independently predict overall survival once other factors were considered. Instead, lower ejection fraction and higher difference in free light chains were the independent predictors in their analysis, and among people treated with daratumumab-based therapy, survival did not differ by the strain category. This adds caution that some heart imaging-based sub-staging ideas may not translate well into today's treatment context for the sickest group. [14]

Looking earlier in the disease course, another observational study linked the risk and timing of developing systemic AL amyloidosis to cumulative exposure to free light chains, especially with lambda type, using large AL and precursor-condition cohorts. In the MGUS and smoldering myeloma cohorts, a minority progressed to AL, and higher free light chain burden predicted earlier development. For patients, this supports a simple idea: longer and higher light-chain exposure appears to raise the chance that AL develops, although the study does not define how any individual person will progress. [15]

One chart review focused on procedures requiring anesthesia in people with AL or ATTR amyloidosis and reported a 30-day all-cause mortality of 1.7% across all encounters, with a higher percentage in AL than ATTR. Endoscopy was the most common procedure, and the mix of procedure types differed between AL and ATTR groups. For patients, this offers some real-world context about short-term outcomes around procedures, while also showing that risks can vary by amyloid type and clinical setting. [16]

A small study from India described systemic amyloidosis cases presenting to rheumatology, where AA amyloidosis was more common than AL in that clinic population, and reported much poorer survival for AL, especially when the heart was involved. While this is not an AL-only cohort and reflects a specific referral setting, it reinforces that cardiac involvement is a major driver of outcomes when AL is present. For patients, it also illustrates that amyloidosis can first show up with joint and stiffness complaints in some healthcare pathways. [17]

What this may mean for patients and caregivers

These studies mostly add understanding about what influences outcomes, rather than changing what any one person should do. They make it clearer that deep control of the light-chain problem is closely tied to better survival and fewer complications in several organs, but that organ healing can be slow and sometimes incomplete. They also highlight complications that may matter during the disease journey, such as clotting and procedure-related risk, and they clarify that not all proposed heart imaging measures reliably predict survival in the most advanced cardiac group.

What individual cases added this month

This month's case reports showed how amyloidosis can first appear in less typical places like the gastrointestinal tract, the eye surface, the mouth, the kidney, or during cancer surgery, and how diagnosis can be delayed when early tests are negative or when symptoms mimic other conditions. Most involved confirmed AL amyloidosis, while in one gastrointestinal case the findings supported AL but the subtype was not definitively established. Across these cases, the consistent message was that confirming amyloid in tissue and then accurately typing it can change the entire interpretation of what is happening. Several cases also showed that local symptoms or imaging findings may not immediately improve even when the underlying light-chain problem responds.

Several cases emphasized tissue proof and accurate typing when the presentation is confusing. A man with chronic stomach pain and weight loss had amyloid deposits across multiple GI sites on biopsy, with lab findings that supported AL, and the report stressed mass spectrometry to confirm the subtype. A younger woman with progressive heart failure had an initially negative biopsy, and diagnosis required expert re-evaluation with polarized light microscopy plus multimodal testing, illustrating that false-negative or missed tissue findings can occur. [18] [19]

Other cases highlighted AL being uncovered through specialty care outside hematology. One report described AL diagnosed from an oral biopsy, later linked to lambda light-chain multiple myeloma, with a large drop in free lambda light chains after daratumumab-based therapy and a later hematologic response reported with elranatamab despite adverse events. Another case found widespread Congo red-positive deposits during lung cancer surgery, with proteomic typing confirming systemic AL (lambda) and prompting hematologic evaluation and treatment. [20] [21]

Kidney-focused cases showed that AL can be limited to the kidneys or can emerge over time in people with other monoclonal-protein kidney diseases. One woman had nephrotic syndrome with renal biopsy-confirmed AL (lambda) amyloidosis but no evidence of multiple myeloma or systemic amyloid elsewhere on evaluation. Another patient with monoclonal gammopathy of renal significance had one kidney disease pattern first and then later developed renal AL amyloidosis on repeat biopsy when the clinical picture changed. [22] [23]

Two cases showed that visible deposits can persist locally even when blood markers improve. In conjunctival AL amyloidosis that later progressed to multiple myeloma, systemic therapy did not shrink the conjunctival lesions, although topical cyclosporine improved discomfort. In mesenteric AL amyloidosis with diffuse calcifications, a very good partial response and a kidney organ response were reported, but the calcifications persisted even after more than 14 months. [24] [25]

What this may mean for patients and caregivers

Case reports do not predict what will happen for most people, but they can help patients recognize the range of ways AL can show up and why diagnosis can be complex. This month's cases reinforce that AL may be discovered through biopsies done for non-blood-related symptoms, and that expert review and amyloid typing can be decisive when earlier tests are negative or unclear. They also help clarify that symptom or imaging changes may not track perfectly with blood response, which can matter for expectations and for how progress is interpreted over time.